- Home
- Publications
- Publication Search
- Publication Details
Title
Antibody-mediated neutralization of SARS-CoV-2
Authors
Keywords
-
Journal
IMMUNITY
Volume -, Issue -, Pages -
Publisher
Elsevier BV
Online
2022-05-13
DOI
10.1016/j.immuni.2022.05.005
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Germinal Centers
- (2022) Gabriel D. Victora et al. Annual Review of Immunology
- Immune imprinting, breadth of variant recognition, and germinal center response in human SARS-CoV-2 infection and vaccination
- (2022) Katharina Röltgen et al. CELL
- Germinal center responses to SARS-CoV-2 mRNA vaccines in healthy and immunocompromised individuals
- (2022) Katlyn Lederer et al. CELL
- SARS-CoV-2 breakthrough infections elicit potent, broad, and durable neutralizing antibody responses
- (2022) Alexandra C. Walls et al. CELL
- mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant
- (2022) Wilfredo F. Garcia-Beltran et al. CELL
- SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses
- (2022) Wanwisa Dejnirattisai et al. CELL
- Mutations in SARS-CoV-2 variants of concern link to increased spike cleavage and virus transmission
- (2022) Alba Escalera et al. Cell Host & Microbe
- Effect of Subcutaneous Casirivimab and Imdevimab Antibody Combination vs Placebo on Development of Symptomatic COVID-19 in Early Asymptomatic SARS-CoV-2 Infection
- (2022) Meagan P. O’Brien et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
- (2022) Obbina Abani et al. LANCET
- Breakthrough infections with SARS-CoV-2 omicron despite mRNA vaccine booster dose
- (2022) Constanze Kuhlmann et al. LANCET
- Hyperimmune immunoglobulin for hospitalised patients with COVID-19 (ITAC): a double-blind, placebo-controlled, phase 3, randomised trial
- (2022) Mark N. Polizzotto et al. LANCET
- Germinal centre-driven maturation of B cell response to mRNA vaccination
- (2022) Wooseob Kim et al. NATURE
- Considerable escape of SARS-CoV-2 Omicron to antibody neutralization
- (2022) Delphine Planas et al. NATURE
- Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron
- (2022) Juan Manuel Carreño et al. NATURE
- Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa
- (2022) Raquel Viana et al. NATURE
- Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies
- (2022) Yunlong Cao et al. NATURE
- Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2
- (2022) Lihong Liu et al. NATURE
- Delayed-interval BNT162b2 mRNA COVID-19 vaccination enhances humoral immunity and induces robust T cell responses
- (2022) Victoria G. Hall et al. NATURE IMMUNOLOGY
- Three exposures to the spike protein of SARS-CoV-2 by either infection or vaccination elicit superior neutralizing immunity to all variants of concern
- (2022) Paul R. Wratil et al. NATURE MEDICINE
- An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies
- (2022) Laura A. VanBlargan et al. NATURE MEDICINE
- mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant
- (2022) Henning Gruell et al. NATURE MEDICINE
- Neutralizing antibodies against the SARS-CoV-2 Delta and Omicron variants following heterologous CoronaVac plus BNT162b2 booster vaccination
- (2022) Eddy Pérez-Then et al. NATURE MEDICINE
- Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants
- (2022) Hung Fu Tseng et al. NATURE MEDICINE
- Protection against SARS-CoV-2 after Covid-19 Vaccination and Previous Infection
- (2022) Victoria Hall et al. NEW ENGLAND JOURNAL OF MEDICINE
- Waning mRNA-1273 Vaccine Effectiveness against SARS-CoV-2 Infection in Qatar
- (2022) Laith J. Abu-Raddad et al. NEW ENGLAND JOURNAL OF MEDICINE
- Duration of Protection against Mild and Severe Disease by Covid-19 Vaccines
- (2022) Nick Andrews et al. NEW ENGLAND JOURNAL OF MEDICINE
- SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster Vaccination
- (2022) Rolando Pajon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial
- (2022) Peter B. Gilbert et al. SCIENCE
- Structural basis for continued antibody evasion by the SARS-CoV-2 receptor binding domain
- (2022) Katherine G. Nabel et al. SCIENCE
- The SARS-CoV-2 monoclonal antibody combination, AZD7442, is protective in non-human primates and has an extended half-life in humans
- (2022) Yueh-Ming Loo et al. Science Translational Medicine
- A human antibody reveals a conserved site on beta-coronavirus spike proteins and confers protection against SARS-CoV-2 infection
- (2022) Panpan Zhou et al. Science Translational Medicine
- Longitudinal analysis of antibody dynamics in COVID-19 convalescents reveals neutralizing responses up to 16 months after infection
- (2022) Yang Yang et al. Nature Microbiology
- No substantial pre-existing B cell immunity against SARS-CoV-2 in healthy adults
- (2022) Meryem Seda Ercanoglu et al. iScience
- mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits similar B cell expansion, neutralizing responses, and protection from Omicron
- (2022) Matthew Gagne et al. CELL
- Analysis of memory B cells identifies conserved neutralizing epitopes on the N-terminal domain of variant SARS-Cov-2 spike proteins
- (2022) Zijun Wang et al. IMMUNITY
- Effect of Sotrovimab on Hospitalization or Death Among High-risk Patients With Mild to Moderate COVID-19
- (2022) Anil Gupta et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Durability of omicron-neutralising serum activity after mRNA booster immunisation in older adults
- (2022) Kanika Vanshylla et al. LANCET INFECTIOUS DISEASES
- Antibody evasion properties of SARS-CoV-2 Omicron sublineages
- (2022) Sho Iketani et al. NATURE
- Increased memory B cell potency and breadth after a SARS-CoV-2 mRNA boost
- (2022) Frauke Muecksch et al. NATURE
- FcγR-mediated SARS-CoV-2 infection of monocytes activates inflammation
- (2022) Caroline Junqueira et al. NATURE
- Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant
- (2022) Nick Andrews et al. NEW ENGLAND JOURNAL OF MEDICINE
- Resistance Mutations in SARS-CoV-2 Delta Variant after Sotrovimab Use
- (2022) Rebecca Rockett et al. NEW ENGLAND JOURNAL OF MEDICINE
- Intramuscular AZD7442 (Tixagevimab–Cilgavimab) for Prevention of Covid-19
- (2022) Myron J. Levin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy of Antiviral Agents against the SARS-CoV-2 Omicron Subvariant BA.2
- (2022) Emi Takashita et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of mRNA Vaccine Boosters against SARS-CoV-2 Omicron Infection in Qatar
- (2022) Laith J. Abu-Raddad et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nirsevimab for Prevention of RSV in Healthy Late-Preterm and Term Infants
- (2022) Laura L. Hammitt et al. NEW ENGLAND JOURNAL OF MEDICINE
- LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants
- (2022) Kathryn Westendorf et al. Cell Reports
- Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19
- (2021) Robert L. Gottlieb et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Evolution of antibody immunity to SARS-CoV-2
- (2021) Christian Gaebler et al. NATURE
- Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults
- (2021) Romina Libster et al. NEW ENGLAND JOURNAL OF MEDICINE
- Convalescent Plasma Antibody Levels and the Risk of Death from Covid-19
- (2021) Michael J. Joyner et al. NEW ENGLAND JOURNAL OF MEDICINE
- Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody
- (2021) C. Garrett Rappazzo et al. SCIENCE
- Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection
- (2021) Jennifer M. Dan et al. SCIENCE
- Prospective mapping of viral mutations that escape antibodies used to treat COVID-19
- (2021) Tyler N. Starr et al. SCIENCE
- Stereotypic neutralizing VH antibodies against SARS-CoV-2 spike protein receptor binding domain in COVID-19 patients and healthy individuals
- (2021) Sang Il Kim et al. Science Translational Medicine
- A therapeutic neutralizing antibody targeting receptor binding domain of SARS-CoV-2 spike protein
- (2021) Cheolmin Kim et al. Nature Communications
- Enhancement versus neutralization by SARS-CoV-2 antibodies from a convalescent donor associates with distinct epitopes on the RBD
- (2021) Yunjiao Zhou et al. Cell Reports
- The antigenic anatomy of SARS-CoV-2 receptor binding domain
- (2021) Wanwisa Dejnirattisai et al. CELL
- Extremely potent human monoclonal antibodies from COVID-19 convalescent patients
- (2021) Emanuele Andreano et al. CELL
- Maturation and persistence of the anti-SARS-CoV-2 memory B cell response
- (2021) Aurélien Sokal et al. CELL
- Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protection
- (2021) Emma S. Winkler et al. CELL
- Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine induced sera
- (2021) Daming Zhou et al. CELL
- Seasonal human coronavirus antibodies are boosted upon SARS-CoV-2 infection but not associated with protection
- (2021) Elizabeth M. Anderson et al. CELL
- Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization
- (2021) Zhuoming Liu et al. Cell Host & Microbe
- Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies
- (2021) Allison J. Greaney et al. Cell Host & Microbe
- Potent SARS-CoV-2 Neutralizing Antibodies Directed Against Spike N-Terminal Domain Target a Single Supersite
- (2021) Gabriele Cerutti et al. Cell Host & Microbe
- Immunogenicity of the Ad26.COV2.S Vaccine for COVID-19
- (2021) Kathryn E. Stephenson et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Emergence of a SARS-CoV-2 variant of concern with mutations in spike glycoprotein
- (2021) Houriiyah Tegally et al. NATURE
- Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7
- (2021) Pengfei Wang et al. NATURE
- mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants
- (2021) Zijun Wang et al. NATURE
- Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies
- (2021) Rita E. Chen et al. NATURE MEDICINE
- Recurrent deletions in the SARS-CoV-2 spike glycoprotein drive antibody escape
- (2021) Kevin R. McCarthy et al. SCIENCE
- Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein
- (2021) Naveenchandra Suryadevara et al. CELL
- N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2
- (2021) Matthew McCallum et al. CELL
- Antibody evasion by the P.1 strain of SARS-CoV-2
- (2021) Wanwisa Dejnirattisai et al. CELL
- B cell genomics behind cross-neutralization of SARS-CoV-2 variants and SARS-CoV
- (2021) Johannes F. Scheid et al. CELL
- Kinetics and correlates of the neutralizing antibody response to SARS-CoV-2 infection in humans
- (2021) Kanika Vanshylla et al. Cell Host & Microbe
- Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial
- (2021) Obbina Abani et al. LANCET
- WHO International Standard for anti-SARS-CoV-2 immunoglobulin
- (2021) Paul A Kristiansen et al. LANCET
- Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection
- (2021) David S. Khoury et al. NATURE MEDICINE
- Delayed production of neutralizing antibodies correlates with fatal COVID-19
- (2021) Carolina Lucas et al. NATURE MEDICINE
- Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant
- (2021) Shabir A. Madhi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19
- (2021) Nicole Doria-Rose et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prior SARS-CoV-2 infection rescues B and T cell responses to variants after first vaccine dose
- (2021) Catherine J. Reynolds et al. SCIENCE
- Prevalent, protective, and convergent IgG recognition of SARS-CoV-2 non-RBD spike epitopes
- (2021) William N. Voss et al. SCIENCE
- The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates
- (2021) Bryan E. Jones et al. Science Translational Medicine
- Cross-reactive serum and memory B-cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection
- (2021) Ge Song et al. Nature Communications
- A SARS-CoV-2 neutralizing antibody with extensive Spike binding coverage and modified for optimal therapeutic outcomes
- (2021) Yu Guo et al. Nature Communications
- Safety, tolerability, pharmacokinetics and immunogenicity of a monoclonal antibody (SCTA01) targeting SARS-CoV-2 in healthy adults: A randomized, double-blind, placebo-controlled, phase I study
- (2021) Yinjuan Li et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In vitro and in vivo functions of SARS-CoV-2 infection-enhancing and neutralizing antibodies
- (2021) Dapeng Li et al. CELL
- Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum
- (2021) Chang Liu et al. CELL
- Memory B cell repertoire for recognition of evolving SARS-CoV-2 spike
- (2021) Pei Tong et al. CELL
- Tackling COVID-19 with neutralizing monoclonal antibodies
- (2021) Davide Corti et al. CELL
- The monoclonal antibody combination REGEN-COV protects against SARS-CoV-2 mutational escape in preclinical and human studies
- (2021) Richard Copin et al. CELL
- SARS-CoV-2 mRNA vaccination induces functionally diverse antibodies to NTD, RBD, and S2
- (2021) Fatima Amanat et al. CELL
- First in Human Study of Bamlanivimab in a Randomized Trial of Hospitalized Patients with COVID‐19
- (2021) Peter Chen et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Safety, Virologic Efficacy, and Pharmacokinetics of CT-P59, a Neutralizing Monoclonal Antibody Against SARS-CoV-2 Spike Receptor-Binding Protein: Two Randomized, Placebo-Controlled, Phase I Studies in Healthy Individuals and Patients With Mild SARS-CoV-2 Infection
- (2021) Jin Yong Kim et al. CLINICAL THERAPEUTICS
- A vaccine-induced public antibody protects against SARS-CoV-2 and emerging variants
- (2021) Aaron J. Schmitz et al. IMMUNITY
- Live imaging of SARS-CoV-2 infection in mice reveals that neutralizing antibodies require Fc function for optimal efficacy
- (2021) Irfan Ullah et al. IMMUNITY
- Affinity maturation of SARS-CoV-2 neutralizing antibodies confers potency, breadth, and resilience to viral escape mutations
- (2021) Frauke Muecksch et al. IMMUNITY
- Temporal maturation of neutralizing antibodies in COVID-19 convalescent individuals improves potency and breadth to circulating SARS-CoV-2 variants
- (2021) Saya Moriyama et al. IMMUNITY
- Effect of Bamlanivimab vs Placebo on Incidence of COVID-19 Among Residents and Staff of Skilled Nursing and Assisted Living Facilities
- (2021) Myron S. Cohen et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Evaluation of Cell-Based and Surrogate SARS-CoV-2 Neutralization Assays
- (2021) Anton M. Sholukh et al. JOURNAL OF CLINICAL MICROBIOLOGY
- SARS-CoV-2 Neutralizing Human Antibodies Protect Against Lower Respiratory Tract Disease in a Hamster Model
- (2021) Bart L Haagmans et al. JOURNAL OF INFECTIOUS DISEASES
- Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial
- (2021) Alberto M Borobia et al. LANCET
- Fc-engineered antibody therapeutics with improved anti-SARS-CoV-2 efficacy
- (2021) Rachel Yamin et al. NATURE
- SARS-CoV-2 infection induces long-lived bone marrow plasma cells in humans
- (2021) Jackson S. Turner et al. NATURE
- Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization
- (2021) Delphine Planas et al. NATURE
- SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses
- (2021) Jackson S. Turner et al. NATURE
- In vivo monoclonal antibody efficacy against SARS-CoV-2 variant strains
- (2021) Rita E. Chen et al. NATURE
- Lectins enhance SARS-CoV-2 infection and influence neutralizing antibodies
- (2021) Florian A. Lempp et al. NATURE
- Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection
- (2021) Zijun Wang et al. NATURE
- SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape
- (2021) Tyler N. Starr et al. NATURE
- High genetic barrier to SARS-CoV-2 polyclonal neutralizing antibody escape
- (2021) Fabian Schmidt et al. NATURE
- Distinct systemic and mucosal immune responses during acute SARS-CoV-2 infection
- (2021) Nikaïa Smith et al. NATURE IMMUNOLOGY
- Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy
- (2021) Sokratis A. Apostolidis et al. NATURE MEDICINE
- Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial
- (2021) Philippe Bégin et al. NATURE MEDICINE
- Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination
- (2021) Joana Barros-Martins et al. NATURE MEDICINE
- Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis
- (2021) Angela Choi et al. NATURE MEDICINE
- Effective high-throughput isolation of fully human antibodies targeting infectious pathogens
- (2021) Lutz Gieselmann et al. Nature Protocols
- SARS-CoV-2 variants, spike mutations and immune escape
- (2021) William T. Harvey et al. NATURE REVIEWS MICROBIOLOGY
- Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19
- (2021) Michael Dougan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant
- (2021) Jamie Lopez Bernal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Subcutaneous REGEN-COV Antibody Combination to Prevent Covid-19
- (2021) Meagan P. O’Brien et al. NEW ENGLAND JOURNAL OF MEDICINE
- Early Convalescent Plasma for High-Risk Outpatients with Covid-19
- (2021) Frederick K. Korley et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Fc-mediated effector functions of a potent SARS-CoV-2 neutralizing antibody, SC31, isolated from an early convalescent COVID-19 patient, are essential for the optimal therapeutic efficacy of the antibody
- (2021) Conrad E. Z. Chan et al. PLoS One
- SARS-CoV-2 escape from a highly neutralizing COVID-19 convalescent plasma
- (2021) Emanuele Andreano et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Immune correlates of protection by mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates
- (2021) Kizzmekia S. Corbett et al. SCIENCE
- Defining variant-resistant epitopes targeted by SARS-CoV-2 antibodies: A global consortium study
- (2021) Kathryn M. Hastie et al. SCIENCE
- Broad betacoronavirus neutralization by a stem helix–specific human antibody
- (2021) Dora Pinto et al. SCIENCE
- Antibodies elicited by mRNA-1273 vaccination bind more broadly to the receptor binding domain than do those from SARS-CoV-2 infection
- (2021) Allison J. Greaney et al. Science Translational Medicine
- Evidence for antibody as a protective correlate for COVID-19 vaccines
- (2021) Kristen A. Earle et al. VACCINE
- Intranasal Administration of a Monoclonal Neutralizing Antibody Protects Mice against SARS-CoV-2 Infection
- (2021) Sandro Halwe et al. Viruses-Basel
- Neutralizing Monoclonal Antibodies That Target the Spike Receptor Binding Domain Confer Fc Receptor-Independent Protection against SARS-CoV-2 Infection in Syrian Hamsters
- (2021) Wen Su et al. mBio
- Sequence signatures of two public antibody clonotypes that bind SARS-CoV-2 receptor binding domain
- (2021) Timothy J. C. Tan et al. Nature Communications
- Mapping mutations to the SARS-CoV-2 RBD that escape binding by different classes of antibodies
- (2021) Allison J. Greaney et al. Nature Communications
- SARS-CoV-2 mucosal antibody development and persistence and their relation to viral load and COVID-19 symptoms
- (2021) Janeri Fröberg et al. Nature Communications
- Convergent antibody responses to the SARS-CoV-2 spike protein in convalescent and vaccinated individuals
- (2021) Elaine C. Chen et al. Cell Reports
- Isolation and characterization of cross-neutralizing coronavirus antibodies from COVID-19+ subjects
- (2021) Madeleine F. Jennewein et al. Cell Reports
- A SARS-CoV-2 neutralizing antibody selected from COVID-19 patients binds to the ACE2-RBD interface and is tolerant to most known RBD mutations
- (2021) Federico Bertoglio et al. Cell Reports
- Prevention and therapy of SARS-CoV-2 and the B.1.351 variant in mice
- (2021) David R. Martinez et al. Cell Reports
- Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study
- (2021) David Hillus et al. Lancet Respiratory Medicine
- Genetic and structural basis for SARS-CoV-2 variant neutralization by a two-antibody cocktail
- (2021) Jinhui Dong et al. Nature Microbiology
- Early cross-coronavirus reactive signatures of humoral immunity against COVID-19
- (2021) Paulina Kaplonek et al. Science Immunology
- Dynamics of SARS-CoV-2 neutralising antibody responses and duration of immunity: a longitudinal study
- (2021) Wan Ni Chia et al. Lancet Microbe
- Responses to a Neutralizing Monoclonal Antibody for Hospitalized Patients With COVID-19 According to Baseline Antibody and Antigen Levels
- (2021) et al. ANNALS OF INTERNAL MEDICINE
- SARS-CoV-2 mRNA vaccination elicits a robust and persistent T follicular helper cell response in humans
- (2021) Philip A. Mudd et al. CELL
- Strong humoral immune responses against SARS-CoV-2 Spike after BNT162b2 mRNA vaccination with a 16-week interval between doses
- (2021) Alexandra Tauzin et al. Cell Host & Microbe
- Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers
- (2021) Kanika Vanshylla et al. Cell Host & Microbe
- Prior infection with SARS-CoV-2 boosts and broadens Ad26.COV2.S immunogenicity in a variant-dependent manner
- (2021) Roanne Keeton et al. Cell Host & Microbe
- Antibody Response and Variant Cross-Neutralization After SARS-CoV-2 Breakthrough Infection
- (2021) Timothy A. Bates et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- How an outbreak became a pandemic: a chronological analysis of crucial junctures and international obligations in the early months of the COVID-19 pandemic
- (2021) Sudhvir Singh et al. LANCET
- Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial
- (2021) Alasdair P S Munro et al. LANCET
- Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial
- (2021) Arabella S V Stuart et al. LANCET
- Anti-SARS-CoV-2 receptor-binding domain antibody evolution after mRNA vaccination
- (2021) Alice Cho et al. NATURE
- Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection
- (2021) Shuo Feng et al. NATURE MEDICINE
- Waning Immunity after the BNT162b2 Vaccine in Israel
- (2021) Yair Goldberg et al. NEW ENGLAND JOURNAL OF MEDICINE
- Neutralization of the SARS-CoV-2 Mu Variant by Convalescent and Vaccine Serum
- (2021) Keiya Uriu et al. NEW ENGLAND JOURNAL OF MEDICINE
- REGEN-COV Antibody Combination and Outcomes in Outpatients with Covid-19
- (2021) David M. Weinreich et al. NEW ENGLAND JOURNAL OF MEDICINE
- Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab
- (2021) Anil Gupta et al. NEW ENGLAND JOURNAL OF MEDICINE
- Plasma Neutralization of the SARS-CoV-2 Omicron Variant
- (2021) Fabian Schmidt et al. NEW ENGLAND JOURNAL OF MEDICINE
- Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months
- (2021) Einav G. Levin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nanometer-resolution in situ structure of the SARS-CoV-2 postfusion spike protein
- (2021) Linhua Tai et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern
- (2021) Rishi R. Goel et al. SCIENCE
- Protection against SARS-CoV-2 Beta variant in mRNA-1273 vaccine–boosted nonhuman primates
- (2021) Kizzmekia S. Corbett et al. SCIENCE
- A broadly cross-reactive antibody neutralizes and protects against sarbecovirus challenge in mice
- (2021) David R. Martinez et al. Science Translational Medicine
- Broad cross-reactivity across sarbecoviruses exhibited by a subset of COVID-19 donor-derived neutralizing antibodies
- (2021) Claudia A. Jette et al. Cell Reports
- Neutralizing antibody 5-7 defines a distinct site of vulnerability in SARS-CoV-2 spike N-terminal domain
- (2021) Gabriele Cerutti et al. Cell Reports
- Monoclonal antibodies protect aged rhesus macaques from SARS-CoV-2-induced immune activation and neuroinflammation
- (2021) Anil Verma et al. Cell Reports
- Long-term immunogenicity of BNT162b2 vaccination in older people and younger health-care workers
- (2021) Pinkus Tober-Lau et al. Lancet Respiratory Medicine
- Mucosal immune response in BNT162b2 COVID-19 vaccine recipients
- (2021) Lorenzo Azzi et al. EBioMedicine
- Naive human B cells engage the receptor binding domain of SARS-CoV-2, variants of concern, and related sarbecoviruses
- (2021) Jared Feldman et al. Science Immunology
- Structural basis for the recognition of the SARS-CoV-2 by full-length human ACE2
- (2020) Renhong Yan et al. SCIENCE
- Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
- (2020) Daniel Wrapp et al. SCIENCE
- Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein
- (2020) Alexandra C. Walls et al. CELL
- SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor
- (2020) Markus Hoffmann et al. CELL
- A Multibasic Cleavage Site in the Spike Protein of SARS-CoV-2 Is Essential for Infection of Human Lung Cells
- (2020) Markus Hoffmann et al. MOLECULAR CELL
- A human neutralizing antibody targets the receptor binding site of SARS-CoV-2
- (2020) Rui Shi et al. NATURE
- Human neutralizing antibodies elicited by SARS-CoV-2 infection
- (2020) Bin Ju et al. NATURE
- Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody
- (2020) Dora Pinto et al. NATURE
- Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor
- (2020) Jun Lan et al. NATURE
- Structural basis of receptor recognition by SARS-CoV-2
- (2020) Jian Shang et al. NATURE
- Antibody responses to SARS-CoV-2 in patients with COVID-19
- (2020) Quan-Xin Long et al. NATURE MEDICINE
- A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2
- (2020) Yan Wu et al. SCIENCE
- A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV
- (2020) Meng Yuan et al. SCIENCE
- DNA vaccine protection against SARS-CoV-2 in rhesus macaques
- (2020) Jingyou Yu et al. SCIENCE
- A human monoclonal antibody blocking SARS-CoV-2 infection
- (2020) Chunyan Wang et al. Nature Communications
- Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients
- (2020) Christoph Kreer et al. CELL
- The Impact of Mutations in SARS-CoV-2 Spike on Viral Infectivity and Antigenicity
- (2020) Qianqian Li et al. CELL
- Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies
- (2020) Christopher O. Barnes et al. CELL
- Potent Neutralizing Antibodies against SARS-CoV-2 Identified by High-Throughput Single-Cell Sequencing of Convalescent Patients’ B Cells
- (2020) Yunlong Cao et al. CELL
- Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus
- (2020) Bette Korber et al. CELL
- Analysis of a SARS-CoV-2-Infected Individual Reveals Development of Potent Neutralizing Antibodies with Limited Somatic Mutation
- (2020) Emilie Seydoux et al. IMMUNITY
- Early safety indicators of COVID-19 convalescent plasma in 5000 patients
- (2020) Michael J. Joyner et al. JOURNAL OF CLINICAL INVESTIGATION
- Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial
- (2020) Pedro M Folegatti et al. LANCET
- Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques
- (2020) Noe B. Mercado et al. NATURE
- Convergent antibody responses to SARS-CoV-2 in convalescent individuals
- (2020) Davide F. Robbiani et al. NATURE
- Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike
- (2020) Lihong Liu et al. NATURE
- Potently neutralizing and protective human antibodies against SARS-CoV-2
- (2020) Seth J. Zost et al. NATURE
- A perspective on potential antibody-dependent enhancement of SARS-CoV-2
- (2020) Ann M. Arvin et al. NATURE
- Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein
- (2020) Seth J. Zost et al. NATURE MEDICINE
- An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
- (2020) Lisa A. Jackson et al. NEW ENGLAND JOURNAL OF MEDICINE
- A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2
- (2020) Xiangyang Chi et al. SCIENCE
- Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies
- (2020) Alina Baum et al. SCIENCE
- Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model
- (2020) Thomas F. Rogers et al. SCIENCE
- Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail
- (2020) Johanna Hansen et al. SCIENCE
- Distinct conformational states of SARS-CoV-2 spike protein
- (2020) Yongfei Cai et al. SCIENCE
- Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability
- (2020) Philip J. M. Brouwer et al. SCIENCE
- Broad neutralization of SARS-related viruses by human monoclonal antibodies
- (2020) Anna Z. Wec et al. SCIENCE
- Structural basis of a shared antibody response to SARS-CoV-2
- (2020) Meng Yuan et al. SCIENCE
- Cryo-EM analysis of the post-fusion structure of the SARS-CoV spike glycoprotein
- (2020) Xiaoyi Fan et al. Nature Communications
- The receptor binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients
- (2020) Lakshmanane Premkumar et al. Science Immunology
- Recognition of the SARS-CoV-2 receptor binding domain by neutralizing antibodies
- (2020) Meng Yuan et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- A Therapeutic Non-self-reactive SARS-CoV-2 Antibody Protects from Lung Pathology in a COVID-19 Hamster Model
- (2020) Jakob Kreye et al. CELL
- Structural and Functional Analysis of the D614G SARS-CoV-2 Spike Protein Variant
- (2020) Leonid Yurkovetskiy et al. CELL
- Loss of Bcl-6-Expressing T Follicular Helper Cells and Germinal Centers in COVID-19
- (2020) Naoki Kaneko et al. CELL
- Molecular Architecture of the SARS-CoV-2 Virus
- (2020) Hangping Yao et al. CELL
- Structurally Resolved SARS-CoV-2 Antibody Shows High Efficacy in Severely Infected Hamsters and Provides a Potent Cocktail Pairing Strategy
- (2020) Shuo Du et al. CELL
- Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity
- (2020) Carolyn Rydyznski Moderbacher et al. CELL
- Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology
- (2020) Luca Piccoli et al. CELL
- Neutralization of SARS-CoV-2 by Destruction of the Prefusion Spike
- (2020) Jiandong Huo et al. Cell Host & Microbe
- Orthogonal SARS-CoV-2 Serological Assays Enable Surveillance of Low Prevalence Communities and Reveal Durable Humoral Immunity.
- (2020) Tyler J. Ripperger et al. IMMUNITY
- Serological Assays Estimate Highly Variable SARS-CoV-2 Neutralizing Antibody Activity in Recovered COVID19 Patients
- (2020) Larry L. Luchsinger et al. JOURNAL OF CLINICAL MICROBIOLOGY
- Receptor binding and priming of the spike protein of SARS-CoV-2 for membrane fusion
- (2020) Donald J. Benton et al. NATURE
- Fc-optimized antibodies elicit CD8 immunity to viral respiratory infection
- (2020) Stylianos Bournazos et al. NATURE
- SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies
- (2020) Christopher O. Barnes et al. NATURE
- Structures and distributions of SARS-CoV-2 spike proteins on intact virions
- (2020) Zunlong Ke et al. NATURE
- Extrafollicular B cell responses correlate with neutralizing antibodies and morbidity in COVID-19
- (2020) Matthew C. Woodruff et al. NATURE IMMUNOLOGY
- Seasonal coronavirus protective immunity is short-lasting
- (2020) Arthur W. D. Edridge et al. NATURE MEDICINE
- Humoral Immune Response to SARS-CoV-2 in Iceland
- (2020) Daniel F. Gudbjartsson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates
- (2020) Edward E. Walsh et al. NEW ENGLAND JOURNAL OF MEDICINE
- REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters
- (2020) Alina Baum et al. SCIENCE
- Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms
- (2020) M. Alejandra Tortorici et al. SCIENCE
- Antibody-mediated disruption of the SARS-CoV-2 spike glycoprotein
- (2020) Antoni G. Wrobel et al. Nature Communications
- An Alternative Binding Mode of IGHV3-53 Antibodies to the SARS-CoV-2 Receptor Binding Domain
- (2020) Nicholas C. Wu et al. Cell Reports
- Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies
- (2020) Wen Shi Lee et al. Nature Microbiology
- Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans
- (2020) Jeffrey Seow et al. Nature Microbiology
- Persistence and decay of human antibody responses to the receptor binding domain of SARS-CoV-2 spike protein in COVID-19 patients
- (2020) Anita S. Iyer et al. Science Immunology
- Compromised Humoral Functional Evolution Tracks with SARS-CoV-2 Mortality
- (2020) Tomer Zohar et al. CELL
- COVID-19-neutralizing antibodies predict disease severity and survival
- (2020) Wilfredo F. Garcia-Beltran et al. CELL
- Quick COVID-19 Healers Sustain Anti-SARS-CoV-2 Antibody Production
- (2020) Yuezhou Chen et al. CELL
- Absence of Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Activity in Prepandemic Sera From Individuals With Recent Seasonal Coronavirus Infection
- (2020) Daniel Poston et al. CLINICAL INFECTIOUS DISEASES
- Germinal Center and Extrafollicular B Cell Responses in Vaccination, Immunity, and Autoimmunity
- (2020) Rebecca A. Elsner et al. IMMUNITY
- Antibody potency, effector function, and combinations in protection and therapy for SARS-CoV-2 infection in vivo
- (2020) Alexandra Schäfer et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Correlates of protection against SARS-CoV-2 in rhesus macaques
- (2020) Katherine McMahan et al. NATURE
- REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19
- (2020) David M. Weinreich et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19
- (2020) NEW ENGLAND JOURNAL OF MEDICINE
- A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia
- (2020) Ventura A. Simonovich et al. NEW ENGLAND JOURNAL OF MEDICINE
- SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19
- (2020) Peter Chen et al. NEW ENGLAND JOURNAL OF MEDICINE
- IgA dominates the early neutralizing antibody response to SARS-CoV-2
- (2020) Delphine Sterlin et al. Science Translational Medicine
- Double lock of a potent human therapeutic monoclonal antibody against SARS-CoV-2
- (2020) Ling Zhu et al. National Science Review
- Defining the features and duration of antibody responses to SARS-CoV-2 infection associated with disease severity and outcome
- (2020) Katharina Röltgen et al. Science Immunology
- Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial
- (2020) Yanjun Zhang et al. LANCET INFECTIOUS DISEASES
- A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics
- (2019) Sabue Mulangu et al. NEW ENGLAND JOURNAL OF MEDICINE
- Assessing human B cell repertoire diversity and convergence
- (2018) Katharina Imkeller et al. IMMUNOLOGICAL REVIEWS
- GISAID: Global initiative on sharing all influenza data – from vision to reality
- (2017) Yuelong Shu et al. Eurosurveillance
- Fcγ Receptor Function and the Design of Vaccination Strategies
- (2017) Stylianos Bournazos et al. IMMUNITY
- Enhanced neonatal Fc receptor function improves protection against primate SHIV infection
- (2014) Sung-Youl Ko et al. NATURE
- Control of Human Viral Infections by Natural Killer Cells
- (2013) Stephanie Jost et al. Annual Review of Immunology
- Antibodies in HIV-1 Vaccine Development and Therapy
- (2013) F. Klein et al. SCIENCE
- Correlates of Protection Induced by Vaccination
- (2010) S. A. Plotkin Clinical and Vaccine Immunology
- Enhanced antibody half-life improves in vivo activity
- (2010) Jonathan Zalevsky et al. NATURE BIOTECHNOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started